2014 Q4 Form 10-K Financial Statement
#000117891314003555 Filed on November 14, 2014
Income Statement
| Concept | 2014 Q4 | 2014 Q3 | 2014 |
|---|---|---|---|
| Revenue | $16.00K | $0.00 | $0.00 |
| YoY Change | -76.12% | -100.0% | |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $600.0K | $890.0K | $2.630M |
| YoY Change | 42.86% | 34.85% | 29.56% |
| % of Gross Profit | |||
| Research & Development | $1.302M | $760.0K | $3.277M |
| YoY Change | 73.6% | 162.07% | 44.23% |
| % of Gross Profit | |||
| Depreciation & Amortization | $1.000K | $10.00K | $6.000K |
| YoY Change | -50.0% | 0.0% | 20.0% |
| % of Gross Profit | |||
| Operating Expenses | $1.302M | $1.650M | $3.277M |
| YoY Change | 73.6% | 71.88% | 44.23% |
| Operating Profit | -$1.902M | -$5.906M | |
| YoY Change | 62.84% | 37.22% | |
| Interest Expense | $10.00K | $20.00K | $138.0K |
| YoY Change | -75.0% | -150.0% | 626.32% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$10.00K | ||
| YoY Change | -200.0% | ||
| Pretax Income | -$1.900M | -$1.620M | -$5.692M |
| YoY Change | 68.99% | 62.0% | 28.28% |
| Income Tax | $0.00 | $0.00 | $4.000K |
| % Of Pretax Income | |||
| Net Earnings | -$1.896M | -$1.630M | -$5.696M |
| YoY Change | 68.68% | 106.33% | 34.59% |
| Net Earnings / Revenue | -11850.0% | ||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$187.4K | -$162.8K | -$616.9K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 10.11M shares | 9.956M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2014 Q4 | 2014 Q3 | 2014 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $24.37M | $21.29M | $21.29M |
| YoY Change | 212.84% | 151.06% | 151.06% |
| Cash & Equivalents | $6.656M | $1.762M | $1.760M |
| Short-Term Investments | $17.71M | $19.53M | $19.53M |
| Other Short-Term Assets | $140.0K | $80.00K | $80.00K |
| YoY Change | -26.32% | 164.86% | 60.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | $27.00K | $78.00K | |
| Total Short-Term Assets | $24.53M | $21.78M | $21.78M |
| YoY Change | 207.18% | 151.94% | 152.08% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $15.00K | $14.00K | $10.00K |
| YoY Change | 70.61% | 133.33% | 0.0% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $10.00K | $0.00 | $0.00 |
| YoY Change | |||
| Other Assets | $10.00K | $10.00K | $10.00K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Total Long-Term Assets | $27.00K | $24.00K | $20.00K |
| YoY Change | 40.52% | 50.0% | 0.0% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $24.53M | $21.78M | $21.78M |
| Total Long-Term Assets | $27.00K | $24.00K | $20.00K |
| Total Assets | $24.56M | $21.80M | $21.80M |
| YoY Change | 206.78% | 151.76% | 151.73% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $800.0K | $930.0K | $930.0K |
| YoY Change | 29.03% | 106.67% | 138.46% |
| Accrued Expenses | |||
| YoY Change | |||
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $827.0K | $973.0K | $970.0K |
| YoY Change | 23.7% | 95.38% | 94.0% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $40.00K | $40.00K | $40.00K |
| YoY Change | 33.33% | 33.33% | 33.33% |
| Total Long-Term Liabilities | $36.00K | $36.00K | $40.00K |
| YoY Change | 12.9% | 16.13% | 33.33% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $827.0K | $973.0K | $970.0K |
| Total Long-Term Liabilities | $36.00K | $36.00K | $40.00K |
| Total Liabilities | $863.0K | $1.009M | $1.010M |
| YoY Change | 23.21% | 90.74% | 90.57% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$29.72M | -$27.82M | |
| YoY Change | 27.82% | 25.75% | |
| Common Stock | $53.32M | $48.16M | |
| YoY Change | 76.45% | 60.8% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $23.70M | $20.79M | $20.79M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $24.56M | $21.80M | $21.80M |
| YoY Change | 206.78% | 151.76% | 151.73% |
Cashflow Statement
| Concept | 2014 Q4 | 2014 Q3 | 2014 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$1.896M | -$1.630M | -$5.696M |
| YoY Change | 68.68% | 106.33% | 34.59% |
| Depreciation, Depletion And Amortization | $1.000K | $10.00K | $6.000K |
| YoY Change | -50.0% | 0.0% | 20.0% |
| Cash From Operating Activities | -$1.399M | -$800.0K | -$4.068M |
| YoY Change | 87.03% | 185.71% | 19.79% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $2.000K | $0.00 | $14.00K |
| YoY Change | -60.0% | -100.0% | 133.33% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $2.000K | $100.0K | -$2.000K |
| YoY Change | -103.42% | -60.0% | |
| Cash From Investing Activities | $1.476M | $90.00K | -$13.09M |
| YoY Change | -1011.11% | -103.07% | 186.45% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $4.833M | $14.89M | |
| YoY Change | 160.49% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | $4.833M | 0.000 | $16.64M |
| YoY Change | -100.0% | 185.71% | |
| NET CHANGE | |||
| Cash From Operating Activities | -$1.399M | -800.0K | -$4.068M |
| Cash From Investing Activities | $1.476M | 90.00K | -$13.09M |
| Cash From Financing Activities | $4.833M | 0.000 | $16.64M |
| Net Change In Cash | $4.910M | -710.0K | -$516.0K |
| YoY Change | -639.56% | -161.21% | -75.9% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.399M | -$800.0K | -$4.068M |
| Capital Expenditures | $2.000K | $0.00 | $14.00K |
| Free Cash Flow | -$1.401M | -$800.0K | -$4.082M |
| YoY Change | 86.06% | 196.3% | 19.99% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014Q3 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
330000 | USD |
| CY2013Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
86500000 | shares |
| CY2013Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
86500000 | shares |
| CY2013Q1 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.083333 | Rate |
| CY2013Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2013Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7200000 | shares |
| CY2013Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7200000 | shares |
| CY2013Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
16700000 | shares |
| CY2012 | us-gaap |
Gain Loss On Sale Of Securities Net
GainLossOnSaleOfSecuritiesNet
|
USD | |
| CY2013 | us-gaap |
Derivative Gain On Derivative
DerivativeGainOnDerivative
|
44000 | USD |
| CY2012 | us-gaap |
Derivative Gain On Derivative
DerivativeGainOnDerivative
|
USD | |
| CY2013 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
19000 | USD |
| CY2014Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
30000000 | shares |
| CY2012 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
13000 | USD |
| CY2013 | us-gaap |
Other Noninterest Expense
OtherNoninterestExpense
|
USD | |
| CY2012 | us-gaap |
Other Noninterest Expense
OtherNoninterestExpense
|
6000 | USD |
| CY2014 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
11000 | USD |
| CY2012 | us-gaap |
Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
|
35000 | USD |
| CY2013 | us-gaap |
Noninterest Expense Commission Expense
NoninterestExpenseCommissionExpense
|
13000 | USD |
| CY2012 | us-gaap |
Noninterest Expense Commission Expense
NoninterestExpenseCommissionExpense
|
15000 | USD |
| CY2013 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
313000 | USD |
| CY2012 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
199000 | USD |
| CY2013Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
956000 | USD |
| CY2014 | us-gaap |
Derivative Loss On Derivative
DerivativeLossOnDerivative
|
USD | |
| CY2013 | us-gaap |
Derivative Loss On Derivative
DerivativeLossOnDerivative
|
USD | |
| CY2012 | us-gaap |
Derivative Loss On Derivative
DerivativeLossOnDerivative
|
143000 | USD |
| CY2014 | us-gaap |
Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
|
USD | |
| CY2014 | us-gaap |
Noninterest Expense Commission Expense
NoninterestExpenseCommissionExpense
|
11000 | USD |
| CY2014 | us-gaap |
Other Noninterest Expense
OtherNoninterestExpense
|
USD | |
| CY2014Q3 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
16000 | USD |
| CY2014 | us-gaap |
Derivative Gain On Derivative
DerivativeGainOnDerivative
|
USD | |
| CY2014 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
138000 | USD |
| CY2014 | us-gaap |
Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
|
7000 | USD |
| CY2014 | us-gaap |
Other Income
OtherIncome
|
USD | |
| CY2014 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
225000 | USD |
| CY2014 | ormp |
Exchange Of Warrants
ExchangeOfWarrants
|
USD | |
| CY2014 | us-gaap |
Gain Loss On Sale Of Securities Net
GainLossOnSaleOfSecuritiesNet
|
80000 | USD |
| CY2013 | ormp |
Exchange Of Warrants
ExchangeOfWarrants
|
297000 | USD |
| CY2013 | us-gaap |
Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
|
3000 | USD |
| CY2012 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
13000 | USD |
| CY2014 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" margin: 8pt 0pt 0pt 82.1pt; text-indent: -36pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;"><strong>a.</strong>              <strong>General</strong></font></p> <p style=" margin: 8pt 0pt 0pt 144pt; text-indent: -36pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;"><strong><font>1</font>)</strong>            <strong>Incorporation and operations</strong></font></p> <p style=" margin: 8pt 0pt 0pt 144pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">Oramed Pharmaceuticals Inc. (the “Company”) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.</font></p> <p style=" margin: 8pt 0pt 0pt 144pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.</font></p> <p style=" margin: 8pt 0pt 0pt 144pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term “Group” refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the “Subsidiary”).</font></p> <p style=" margin: 8pt 0pt 0pt 144pt; text-indent: -36pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;"><strong><font>2</font>)</strong>            <strong>Development and liquidity risks</strong></font></p> <p style=" margin: 8pt 0pt 0pt 144pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">The Group is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated any revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.</font></p> <p style=" margin: 8pt 0pt 0pt 144pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be <font>no</font> assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.</font></p> <p style=" margin: 8pt 0pt 0pt 144pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">Based on its current cash resources and commitments, and cash received in private and public offerings in the years ended August 31, 2014 and 2013, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond after the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.</font></p> <p style=" margin: 8pt 0pt 0pt 144pt; text-indent: -36pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;"><strong><font>3</font>)            Reverse stock split</strong></font></p> <p style=" margin: 8pt 0pt 0pt 144pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">On January 10, 2013, the Company's Board of Directors approved a reverse stock split at a ratio of <font>one</font>-for-<font>twelve</font>, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of January 23, 2013, from approximately <font>86.5</font> million shares to approximately <font>7.2</font> million shares and the number of authorized common shares from <font>200</font> million shares to approximately <font>16.7</font> million shares. All share and per share data were retrospectively adjusted as a result of the split.</font></p> </div> | |
| CY2014 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" margin: 8pt 0pt 0pt 82.1pt; text-indent: -36pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;"><strong>c.</strong>            <strong>Use of estimates in the preparation of financial statements</strong></font></p> <p style=" margin: 8pt 0pt 0pt 80.65pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.</font></p> <p style=" margin: 8pt 0pt 0pt 80.65pt; font-family : Times New Roman;"><font style=" font-family : Times New Roman; font-size: 10pt;">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation.</font></p> </div> | |
| CY2014Q3 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
3000 | USD |
| CY2013Q3 | us-gaap |
Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
|
5000 | USD |
| CY2014Q3 | us-gaap |
Prepaid Pension Costs
PrepaidPensionCosts
|
7000 | USD |
| CY2013Q3 | us-gaap |
Prepaid Pension Costs
PrepaidPensionCosts
|
5000 | USD |
| CY2014 | us-gaap |
Depreciation
Depreciation
|
6000 | USD |
| CY2014Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
14000 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
5000 | USD |
| CY2012 | us-gaap |
Depreciation
Depreciation
|
15000 | USD |
| CY2014Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
144000 | USD |
| CY2013Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
130000 | USD |
| CY2014Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
130000 | USD |
| CY2013Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
124000 | USD |
| CY2013Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
6000 | USD |
| CY2014Q3 | us-gaap |
Assets
Assets
|
21802000 | USD |
| CY2013Q3 | us-gaap |
Assets
Assets
|
8660000 | USD |
| CY2014Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
926000 | USD |
| CY2013Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
434000 | USD |
| CY2014Q3 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
47000 | USD |
| CY2013Q3 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
64000 | USD |
| CY2014Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
973000 | USD |
| CY2013Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
498000 | USD |
| CY2014Q3 | us-gaap |
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
|
9000 | USD |
| CY2013Q3 | us-gaap |
Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
|
8000 | USD |
| CY2014 | ormp |
Severance Pay Insurance Deposits
SeverancePayInsuranceDeposits
|
2000 | USD |
| CY2014 | us-gaap |
Severance Costs1
SeveranceCosts1
|
26000 | USD |
| CY2013 | us-gaap |
Severance Costs1
SeveranceCosts1
|
23000 | USD |
| CY2014 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
26000 | USD |
| CY2013 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
13000 | USD |
| CY2014Q3 | ormp |
Severance Pay Insurance Deposit Expected Amount
SeverancePayInsuranceDepositExpectedAmount
|
27000 | USD |
| CY2013 | ormp |
Severance Pay Insurance Deposits
SeverancePayInsuranceDeposits
|
2000 | USD |
| CY2012 | ormp |
Severance Pay Insurance Deposits
SeverancePayInsuranceDeposits
|
4000 | USD |
| CY2012 | us-gaap |
Severance Costs1
SeveranceCosts1
|
6000 | USD |
| CY2012 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
7000 | USD |
| CY2013 | us-gaap |
Gain Loss On Sale Of Securities Net
GainLossOnSaleOfSecuritiesNet
|
90000 | USD |
| CY2012 | ormp |
Exchange Of Warrants
ExchangeOfWarrants
|
USD | |
| CY2013 | us-gaap |
Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
|
USD | |
| CY2013 | us-gaap |
Other Income
OtherIncome
|
27000 | USD |
| CY2012 | us-gaap |
Other Income
OtherIncome
|
USD | |
| CY2013 | us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
180000 | USD |
| CY2014Q3 | us-gaap |
Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
|
27000 | USD |
| CY2013Q3 | us-gaap |
Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
|
23000 | USD |
| CY2014Q3 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
36000 | USD |
| CY2013Q3 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
31000 | USD |
| CY2014Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.012 | |
| CY2014Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
30000000 | shares |
| CY2013Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
16666667 | shares |
| CY2014Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
10102555 | shares |
| CY2013Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7937872 | shares |
| CY2014Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
121000 | USD |
| CY2013Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
95000 | USD |
| CY2014Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
452000 | USD |
| CY2013Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
304000 | USD |
| CY2014Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
48040000 | USD |
| CY2013Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
29856000 | USD |
| CY2014Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-27820000 | USD |
| CY2013Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-22124000 | USD |
| CY2014Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20793000 | USD |
| CY2013Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8131000 | USD |
| CY2014Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
21802000 | USD |
| CY2013Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
8660000 | USD |
| CY2014Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1762000 | USD |
| CY2013Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2272000 | USD |
| CY2014Q3 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
18481000 | USD |
| CY2013Q3 | us-gaap |
Deposits Assets Current
DepositsAssetsCurrent
|
5247000 | USD |
| CY2014Q3 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
1047000 | USD |
| CY2014Q3 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
16000 | USD |
| CY2013Q3 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
16000 | USD |
| CY2014Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
64000 | USD |
| CY2013Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
90000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-2301000 | USD |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
14000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2000 | USD |
| CY2013Q3 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
5000 | USD |
| CY2014Q3 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
78000 | USD |
| CY2013Q3 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
58000 | USD |
| CY2014Q3 | us-gaap |
Assets Current
AssetsCurrent
|
21778000 | USD |
| CY2013Q3 | us-gaap |
Assets Current
AssetsCurrent
|
8644000 | USD |
| CY2014Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.012 | |
| CY2014Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
10102555 | shares |
| CY2013Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
7937872 | shares |
| CY2013Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2014 | ormp |
Non Cash Investing And Financing Activities Shares And Warrants To Be Issued For Cash
NonCashInvestingAndFinancingActivitiesSharesAndWarrantsToBeIssuedForCash
|
USD | |
| CY2013 | ormp |
Non Cash Investing And Financing Activities Shares And Warrants To Be Issued For Cash
NonCashInvestingAndFinancingActivitiesSharesAndWarrantsToBeIssuedForCash
|
USD | |
| CY2012 | ormp |
Non Cash Investing And Financing Activities Shares And Warrants To Be Issued For Cash
NonCashInvestingAndFinancingActivitiesSharesAndWarrantsToBeIssuedForCash
|
25000 | USD |
| CY2011Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
USD | |
| CY2012 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
494000 | USD |
| CY2012 | ormp |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
|
143000 | USD |
| CY2012 | ormp |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Exchange Of Warrants
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisExchangeOfWarrants
|
USD | |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5696000 | USD |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4232000 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3344000 | USD |
| CY2014 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6000 | USD |
| CY2013 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
5000 | USD |
| CY2012 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
15000 | USD |
| CY2014 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
29000 | USD |
| CY2013 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-19000 | USD |
| CY2012 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-62000 | USD |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1468000 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
719000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
271000 | USD |
| CY2014 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
102000 | USD |
| CY2013 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
244000 | USD |
| CY2012 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
108000 | USD |
| CY2014 | us-gaap |
Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
|
80000 | USD |
| CY2013 | us-gaap |
Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
|
50000 | USD |
| CY2012 | us-gaap |
Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
|
USD | |
| CY2014 | us-gaap |
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
|
USD | |
| CY2013 | us-gaap |
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
|
USD | |
| CY2012 | us-gaap |
Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
|
184000 | USD |
| CY2014 | ormp |
Warrants Exchanged
WarrantsExchanged
|
USD | |
| CY2013 | ormp |
Warrants Exchanged
WarrantsExchanged
|
297000 | USD |
| CY2014 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
USD | |
| CY2013 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
45000 | USD |
| CY2012 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
-143000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
319000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
31000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
475000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-146000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
203000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
|
1000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
|
1000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
|
-2000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
4000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-205000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
90000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4068000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3396000 | USD |
| CY2013 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
918000 | USD |
| CY2012 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
USD | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-13088000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-4569000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
1769000 | USD |
| CY2014 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
14887000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
5715000 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
3489000 | USD |
| CY2014 | ormp |
Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
|
1753000 | USD |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
2918000 | USD |
| CY2012Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4431000 | USD |
| CY2011Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1513000 | USD |
| CY2014 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
USD | |
| CY2014 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
55750000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
5847000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
475000 | USD |
| CY2014 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
42539000 | USD |
| CY2013 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
1054000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
1800000 | USD |
| CY2014 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
137000 | USD |
| CY2013 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
227000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
450000 | USD |
| CY2014 | ormp |
Payments To Acquire Funds In Respect Of Employee Rights Upon Retirement
PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement
|
2000 | USD |
| CY2013 | ormp |
Payments To Acquire Funds In Respect Of Employee Rights Upon Retirement
PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement
|
2000 | USD |
| CY2012 | ormp |
Payments To Acquire Funds In Respect Of Employee Rights Upon Retirement
PaymentsToAcquireFundsInRespectOfEmployeeRightsUponRetirement
|
4000 | USD |
| CY2014 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
-2000 | USD |
| CY2013 | us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
-5000 | USD |
| CY2013 | ormp |
Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
|
109000 | USD |
| CY2012 | ormp |
Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
|
USD | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
16640000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5824000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3489000 | USD |
| CY2014 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
6000 | USD |
| CY2013 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-18000 | USD |
| CY2012 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
-39000 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-510000 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2159000 | USD |
| CY2012 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
USD | |
| CY2014 | us-gaap |
Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
|
USD | |
| CY2013 | us-gaap |
Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
|
628000 | USD |
| CY2012 | us-gaap |
Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
|
USD | |
| CY2012 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
USD | |
| CY2014Q3 | us-gaap |
Interest Bearing Deposits In Banks
InterestBearingDepositsInBanks
|
18481000 | USD |
| CY2013Q3 | us-gaap |
Interest Bearing Deposits In Banks
InterestBearingDepositsInBanks
|
5247000 | USD |
| CY2012Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
637000 | USD |
| CY2013 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
28000 | USD |
| CY2013 | ormp |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValue
|
-44000 | USD |
| CY2013 | ormp |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Exchange Of Warrants
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisExchangeOfWarrants
|
-621000 | USD |
| CY2013Q3 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
USD | |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2272000 | USD |
| CY2014 | ormp |
Marketable Securities Sold
MarketableSecuritiesSold
|
2625989 | shares |
| CY2014Q3 | ormp |
Marketable Securities Ownership Percentage
MarketableSecuritiesOwnershipPercentage
|
0.098 | pure |
| CY2012 | us-gaap |
Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
|
USD | |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3277000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
304000 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
80000 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
|
14887000 | USD |
| CY2014 | ormp |
Stock Issued During Period Value Liquidation Damage Fee
StockIssuedDuringPeriodValueLiquidationDamageFee
|
102000 | USD |
| CY2014 | ormp |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
1753000 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1468000 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
148000 | USD |
| CY2011Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3723000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
271000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
108000 | USD |
| CY2012 | ormp |
Shares And Warrants To Be Issued For Cash Value
SharesAndWarrantsToBeIssuedForCashValue
|
25000 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2995000 | USD |
| CY2013 | ormp |
Marketable Securities Sold
MarketableSecuritiesSold
|
5250000 | shares |
| CY2014Q3 | us-gaap |
Trading Securities Equity Cost
TradingSecuritiesEquityCost
|
590000 | USD |
| CY2013Q3 | us-gaap |
Trading Securities Equity Cost
TradingSecuritiesEquityCost
|
652000 | USD |
| CY2014 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
|
138000 | USD |
| CY2013 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
|
170000 | USD |
| CY2013Q1 | ormp |
Marketable Securities Sold
MarketableSecuritiesSold
|
1750000 | shares |
| CY2013Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
|
56000 | USD |
| CY2014Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
953369 | shares |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5692000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4437000 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1681000 | USD |
| CY2014 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2629000 | USD |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2032000 | USD |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1203000 | USD |
| CY2014 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5906000 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4304000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2884000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3254000 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
4000 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-205000 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
90000 | USD |
| CY2014 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
34000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
131000 | USD |
| CY2012 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
USD | |
| CY2013 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
90000 | USD |
| CY2012 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
USD | |
| CY2014 | us-gaap |
Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
|
194000 | USD |
| CY2013 | us-gaap |
Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
|
263000 | USD |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.010375 | pure |
| CY2013 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
1124000 | USD |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | pure |
| CY2014 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-5548000 | USD |
| CY2013 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3928000 | USD |
| CY2012 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-3344000 | USD |
| CY2014 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.62 | |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.59 | |
| CY2012 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.57 | |
| CY2014 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
9244059 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
7209283 | shares |
| CY2012 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
5884595 | shares |
| CY2012Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3778000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1422000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
|
4239000 | USD |
| CY2013 | ormp |
Stock Issued During Period Value Marketable Securities
StockIssuedDuringPeriodValueMarketableSecurities
|
628000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
245000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
918000 | USD |
| CY2013 | ormp |
Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
|
110000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
719000 | USD |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7603 | pure |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0083 | pure |
| CY2012Q3 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
3190000 | USD |
| CY2012Q3 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
18000 | USD |
| CY2012Q3 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
3208000 | USD |
| CY2012Q3 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
USD | |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-599000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-2655000 | USD |
| CY2012 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
-8000 | USD |
| CY2012 | us-gaap |
Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
|
98000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1139000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
517000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
120000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
502000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
90000 | USD |
| CY2011Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
138000 | USD |
| CY2012 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
90000 | USD |
| CY2014 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
1246000 | USD |
| CY2011Q3 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
1813000 | USD |
| CY2012 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
1395000 | USD |
| CY2014Q4 | ormp |
Finders Fee
FindersFee
|
150000 | USD |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.8206 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0165 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | pure |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.6435 | pure |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.7546 | pure |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0092 | pure |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0101 | pure |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | pure |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
374000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
480000 | USD |
| CY2014 | us-gaap |
Income Tax Examination Penalties Expense
IncomeTaxExaminationPenaltiesExpense
|
0 | USD |
| CY2013 | us-gaap |
Income Tax Examination Penalties Expense
IncomeTaxExaminationPenaltiesExpense
|
0 | USD |
| CY2014 | us-gaap |
Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
|
4000 | USD |
| CY2013 | us-gaap |
Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
|
-192000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1992000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-1552000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
1104000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
902000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
408000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
|
276000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
4000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
|
-205000 | USD |
| CY2013Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
23000 | USD |
| CY2012Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
228000 | USD |
| CY2014 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
4000 | USD |
| CY2013 | us-gaap |
Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
|
-205000 | USD |
| CY2014Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
27000 | USD |
| CY2014Q3 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
USD | |
| CY2013Q3 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
USD | |
| CY2014Q3 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
688000 | USD |
| CY2014 | dei |
Entity Registrant Name
EntityRegistrantName
|
ORAMED PHARMACEUTICALS INC. | |
| CY2014 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001176309 | |
| CY2014 | dei |
Document Type
DocumentType
|
10-K | |
| CY2014 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-08-31 | |
| CY2014 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--08-31 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | pure |
| CY2014Q3 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
6626000 | USD |
| CY2013Q3 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
5605000 | USD |
| CY2014Q3 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
4890000 | USD |
| CY2013Q3 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
3993000 | USD |
| CY2013Q3 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
339000 | USD |
| CY2014Q3 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
5578000 | USD |
| CY2013Q3 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
4332000 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-893000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-1186000 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-4799000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-3251000 | USD |
| CY2014 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
USD | |
| CY2013 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
-13000 | USD |
| CY2014 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2014 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2014 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2014 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2014Q1 | dei |
Entity Public Float
EntityPublicFloat
|
128906265 | USD |
| CY2014Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
10106305 | shares |
